Partner Therapeutics Receives Orphan Drug Designation for Leukine (sargramostim) – Odessa American

LEXINGTON, Mass., Sept. 19, 2019 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), for the potential treatment of Stage IIb-IV melanoma.

Melanoma is the most aggressive form of skin cancer and rates of melanoma have been rising for the past 30 years. The American Cancer Society estimates 96,480 new melanoma cases will be diagnosed in the US and 7,230 people will die from the disease in 2019. The FDA grants orphan drug designation to promote the development of promising treatments for conditions that affect 200,000 or fewer U.S. patients annually. If a product holding Orphan Drug Designation receives the first FDA approval for the disease in which it has such designation the company qualifies for, among other things, seven years of market exclusivity following marketing approval.

The Eastern Cooperative Oncology Group (ECOG) previously reported results of Study 1608, a Phase II study in which patients with advanced stage melanoma received a combination of sargramostim and ipilimumab or ipilimumab alone1. Among 245 patients, the addition of sargramostim led to longer survival (median 17.5 vs 12.7 months). The most common Grade 3-5 toxicities in patients treated with sargramostim and ipilimumab were diarrhea (12.7%) and rash (9.3%) and occurred at similar rate in patients receiving ipilimumab alone. Overall, severe toxicities occurred less frequently in patients treated with sargramostim plus ipilimumab vs ipilimumab alone (44.9% vs 58.3%, Grade 3-5); the most notable reductions were in gastrointestinal and pulmonary toxicities. The results of this study led to initiation of a larger Phase 2/3 study (ECOG 6141) evaluating sargramostim in combination with ipilimumab and nivolumab as initial treatment of advanced or metastatic melanoma. This ongoing study is being conducted by ECOG with support from the National Cancer Institute.2

"Leukine's role as an immunomodulator was not the initial focus when it was first discovered decades ago. As we learn more about the immunologic effects of GM-CSF on antitumor immunity, we believe there is potential to develop Leukine to help more patients benefit from treatment with checkpoint inhibitors in melanoma and other difficult to treat cancers," said Bob Mulroy, PTx's CEO. "This orphan designation is an important step in the development of Leukine. We are pleased FDA has programs such as Orphan Drug Designation to support research in rare diseases."

Leukine was initially approved in the United States in 1991 and has five hematologic oncologic indications. Leukine is currently not approved for the treatment of melanoma. The approval of an orphan drug designation request does not alter the standard regulatory requirements and processes for obtaining marketing approval of an investigational drug. Sponsors must establish safety and efficacy of a compound in the treatment of a disease through adequate and well-controlled studies.

Please see full Prescribing Information for LEUKINE at http://www.leukine.com

About Leukine (sargramostim)

Leukine is a yeast-derived recombinant humanized granulocyte-macrophage colony stimulating factor (rhuGM-CSF) and the only FDA approved GM-CSF. GM-CSF is an important leukocyte growth factor known to play a key role in hematopoiesis, effecting the growth and maturation of multiple cell lineages as well as the functional activities of these cells in antigen presentation and cell mediated immunity3.

Important Safety Information for LEUKINE (sargramostim)

Contraindications

LEUKINE is contraindicated in patients with known hypersensitivity to human granulocyte-macrophage colony stimulating factor such as sargramostim (GM-CSF), yeast-derived products, or any component of LEUKINE.

Warnings and Precautions

Serious hypersensitivity reactions, including anaphylactic reactions, have been reported with LEUKINE. If any serious allergic or anaphylactic reaction occurs, immediately discontinue LEUKINE therapy and institute medical management. Permanently discontinue LEUKINE in patients with serious allergic reactions.LEUKINE can cause infusion-related reactions, including respiratory distress, hypoxia, flushing, hypotension, syncope and/or tachycardia. Observe closely during infusion, particularly in patients with preexisting lung disease, as dose adjustment or discontinuation may be required.Do not administer LEUKINE simultaneously with or within 24 hours preceding cytotoxic chemotherapy or radiotherapy or within 24 hours following chemotherapy.Edema, capillary leak syndrome, pleural and/or pericardial effusion have been reported in patients after LEUKINE administration. LEUKINE should be used with caution and monitored in patients with preexisting fluid retention, pulmonary infiltrates, or congestive heart failure.Supraventricular arrhythmia has been reported in uncontrolled studies during LEUKINE administration, particularly in patients with a previous history of cardiac arrhythmia. Use LEUKINE with caution in patients with preexisting cardiac disease.If ANC > 20,000 cells/mm3 or if WBC counts > 50,000/mm3, LEUKINE administration should be interrupted or the dose reduced by half. Twice weekly monitoring of CBC with differential should be performed.LEUKINE therapy should be discontinued if disease progression is detected during treatment.Treatment with LEUKINE may induce neutralizing anti-drug antibodies. Use LEUKINE for the shortest duration required.Liquid solutions containing benzyl alcohol (including LEUKINE Injection) or LEUKINE for Injection reconstituted with Bacteriostatic Water for Injection, USP (0.9% benzyl alcohol) should not be administered to neonates and low birth weight infants.Concomitant use of drugs that can potentiate the myeloproliferative effects of LEUKINE should be avoided.

Adverse Reactions

Adverse events occurring in >10% of patients receiving LEUKINE in controlled clinical trials and reported in a higher frequency than placebo are:

In Autologous bone marrow transplantation (BMT) patientsasthenia, malaise, diarrhea, rash, peripheral edema, urinary tract disorderIn Allogeneic BMT patientsabdominal pain, chills, chest pain, diarrhea, nausea, vomiting, hematemesis, dysphagia, GI hemorrhage, pruritus, bone pain, arthralgia, eye hemorrhage, hypertension, tachycardia, bilirubinemia, hyperglycemia, increase creatinine, hypomagnesemia, edema, pharyngitis, epistaxis, dyspnea, insomnia, anxiety, high glucose, low albuminIn AML patientsfever, weight loss, nausea, vomiting, anorexia, skin reactions, metabolic laboratory abnormalities, edema

Please see full Prescribing Information for LEUKINE at http://www.leukine.com

Indications and Usage

LEUKINE (sargramostim) is a leukocyte growth factor indicated for the following uses:

LEUKINE is indicated to shorten time to neutrophil recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML).LEUKINE is indicated in adult patients with cancer undergoing autologous hematopoietic stem cell transplantation for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis.LEUKINE is indicated for the acceleration of myeloid reconstitution following autologous peripheral blood progenitor cell (PBPC) or bone marrow transplantation in adult and pediatric patients 2 years of age and older with non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and Hodgkin's lymphoma (HL).LEUKINE is indicated for the acceleration of myeloid reconstitution in adult and pediatric patients 2 years of age and older undergoing allogeneic bone marrow transplantation from HLA-matched related donors.LEUKINE is indicated for the treatment of adult and pediatric patients 2 years and older who have undergone allogeneic or autologous bone marrow transplantation in whom neutrophil recovery is delayed or failed.LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).

About Partner Therapeutics, Inc.:

PTx is an integrated commercial-stage biotech company focused on the development and commercialization of therapeutics that improve health outcomes in the treatment of cancer. PTx's development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company believes in delivering great products with the purpose of creating the best possible outcomes for patients and their families.

References: 1. Hodi FS, et al. Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma A Randomized Clinical Trial. JAMA. 2014;312(17):1744-1753

2. National Cancer Institute. Nivolumab and ipilimumab with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery. Available at: https://clinicaltrials.gov/ct2/show/NCT02339571. NLM identifier: NCT02339571. Accessed August 26, 2019

3. Armitage JO. Blood. 1998;92(12):4491-4508

View original content to download multimedia: http://www.prnewswire.com/news-releases/partner-therapeutics-receives-orphan-drug-designation-for-leukine-sargramostim-300921156.html

SOURCE Partner Therapeutics, Inc.

Read more:
Partner Therapeutics Receives Orphan Drug Designation for Leukine (sargramostim) - Odessa American

Stem Cells Market Predicted to Surpass US$167.33 Bn By 2025 – TheSlapClap

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Request a Sample of Stem Cells Market Report

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

This review is based on the findings of a TMR report, titled, Stem Cells Market (Product Adult Stem Cell, Human Embryonic Stem Cell, and Induced Pluripotent Stem; Sources Autologous and Allogeneic; Application Regenerative Medicine and Drug Discovery and Development; End Users Therapeutic Companies, Cell and Tissues Banks, Tools and Reagent Companies, and Service Companies) Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 20172025.

Read the original post:
Stem Cells Market Predicted to Surpass US$167.33 Bn By 2025 - TheSlapClap

Story of life: Seven wonders of biological research – The Irish Times

Everyone has heard of the seven wonders of the ancient world. Today I present my verdict on seven wonder discoveries in biological research, listed in rough chronological order.

Wonder 1: Cell TheoryCell theory, formulated in 1839, made three assertions: (a) All organisms are composed of basic units called cells; (b) The cell is the basic unit of structure and organisation in all living organisms; (c) New cells arise only from pre-existing cells.

Cell theory rationalised basic biology and contradicted the common notion that life can arise spontaneously from non-living matter.

Wonder 2: The Theory of Evolution Through Natural Selection.This is the most significant-ever insight into biology and was jointly proposed in 1858 by Charles Darwin (1809-1882) and Alfred Russell Wallace (1823-1913). It was already known that life on earth changes over long time periods. The theory of evolution explained the mechanism underpinning these changes natural selection. This theory draws all biology together into one unified framework. In its absence, biology would be reduced to a vast catalogue of unrelated observations.

Wonder 3: The Chemistry of LifeLife, unlike mechanical machines, works close to room temperature and without the assistance of significant temperature or pressure gradients. How then do cells grow, divide and create local order in a world that otherwise moves towards increasing disorder? This question was answered by biochemistry the chemistry of life.

A living cell is the end product of co-ordinated reactions between its innumerable chemical constituents metabolism. These reactions must proceed fast enough at room temperature to sustain life, and this is enabled by protein catalysts called enzymes, discovered in the 1800s. Cell metabolism is driven by energy, ultimately supplied by sunlight.

Wonder 4: Antibiotics and VaccinationsAntibiotics, discovered in 1928, are used to kill pathogenic microbes, and vaccination to provide immunity against disease has been in widespread use since 1900. Vaccination has eliminated many deadly diseases, including smallpox and polio.

Average life expectancy in 1900 was 50 years; today that figure is 82 years. Antibiotics and immunisation are one significant cause of this improvement. If we lost antibiotics and vaccinations today, life expectancy would gradually revert to 50-60 years.

Wonder 5: Discovering the Structure of DNAFaithful inheritance of parental characteristics by offspring is essential for biological evolution. The nature of the cells hereditary material was identified as nucleic acid (DNA) in 1944. In 1953, James Watson (born in 1928) and Francis Crick (1916-2004) made the greatest biological discovery of the 20th century when they solved the structure of DNA, a discovery that also indicated how DNA replicates and transmits genetic information from generation to generation.

DNA is a long molecule made of four sub-units A,T,G,C. Genetic information is encoded in the linear sequence (genes) of these subunits, dictating the structure/activity of all cell proteins, including all enzymes, thereby controlling the activities of the cell. Understanding DNA unlocked the secret of the molecular logic of life.

Wonder 6: CloningEvery animal body cell, including cells of the early embryo, contains a full set of the animals genes. Therefore, inducing any body cell into developing as embryonic cells develop should produce a genetic copy of the animal a clone. In 1996 Dolly the sheep was cloned in this manner.

Cloning offers many huge potential benefits, eg cloning animals, genetically modified to secrete a human hormone, to produce herds secreting large quantities of the hormone for use by patients deficient in the hormone. Cloning could also rebuild endangered animal populations or revive extinct animals.

Wonder 7: Induced Pluripotent Stem CellsThe human body is composed of over 200 tissues/organs skin, liver etc. Each tissue cell is differentiated to do a particular job. But all tissue cells develop from embryonic undifferentiated pluripotent stem cells.

In 2006 Shinya Yamanaka discovered how to transform differentiated body cells into pluripotent stem cells. These induced pluripotent stem cells (IPSC) can be coaxed to develop into specific adult tissues.

IPSCs have huge potential in many areas, eg regenerative medicine. New organs could be grown from patients own IPSCs to replace failing organs and without fear of immune rejection.

IPSCs are extremely useful for many research purposes, eg testing new drugs, and can substitute for stem cells extracted from human embryos, thereby avoiding ethical problems.

William Reville is an emeritus professor of biochemistry at UCC

Read the original here:
Story of life: Seven wonders of biological research - The Irish Times

Cell Harvester Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2025 – Market Forecast

Cell harvester is a device in which cells are regenerate, and that regenerative cells further used in transplantation and repair the affected organs. Biopharmaceuticals industry and related downstream process are mainly dependent on cell harvesting techniques. Cell harvester plays an important role in treating various types of diseases such as cancers, immune-deficiency related diseases, blood-related disorder, etc. In some Burn cases, cell harvesting is also beneficial to the victim in the form of grafting new skin cells. Several Bio-Pharma companies are trying to manufacture regenerating medicine by focusing regenerative myocardial tissue ability by cell grafting method in which adult stem cell injected into the patient. Cell harvester can also be used in eye disease treatment. Some companies are also manufacturing such devices which consist passive flexible drilling unit as well as cell harvesting system that are used in bone marrow transplantation. Cell harvesters market is growing tremendously due to the broad spectrum of cell harvester usage. Biopharmaceutical Company's attractiveness towards regenerative medicine is the reason for the rapid increment of the cell harvester market growth.

Cell Harvester market: Drivers and Restraint

Increasing incidence and prevalence of blood cancer, blood-related disease, increasing organ transplantation procedure rate, improving healthcare expenditure are considered as the driver for the cell harvester market. Multipurpose use of cell harvester also drives the growth of cell harvester market. The complexity of the procedure, less of awareness and lack of reimbursement, this factor may restrain the growth of cell harvester market.

Cell harvester market: Segmentation

The global market for Cell Harvester segmented by product type, modality, end user, and geography:

Based on modality, Automated Manual Auto-trap

Based on application Cell Proliferation Assays Mixed Lymphocyte Culture (MLC) Assays Receptor-binding Assays Single-Stranded Template DNA Harvesting

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/cell-harvester-market.html

Based on end-user Research Centers Academics Institutes Diagnostic Labs Hospitals

Segmented by geography North America Latin America Europe Asia Pacific The Middle East and Africa

Cell Harvester Market: Overview

Cell harvesting systems market shows promising growth owing to equipment efficacy and accuracy during cells harvest. By application type, Cell Proliferation Assays is anticipated to hold the major share in the cell harvesting systems market owing to less process error, safe and simple procedure and fewer side effects.

By product modality, cell harvester segmented into three categories whereas, automated cell harvester devices are widely used in worldwide.

Based on the end user, cell harvester can be used by several end user such as research centers. Hospital ,Academic Institutes, etc., research center, share large percentage as end user followed by the hospital.

Cell Harvester Market: Region-wise Outlook

By regional, global Cell Harvester market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. Asia Pacific dominates the global cell harvester market followed by Europe and will continue to dominate the global Cell Harvester market attributed to holding high potential and rising growth in terms of wide acceptance of cell harvester technology. Furthermore, increasing rate of procedures and improving healthcare expenditure also expected to boost the global cell harvester market over the forecasted period. North America is expecting emerging market for the cell harvester market.

Request Brochure of this report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22721&source=atm

Cell Harvester Market: Key Market Participants

Key players of the cell harvesting systems market are PerkinElmer Inc. Tomtec, Bertin Technologies, TERUMO BCT, INC., hynoDent AG, Avita Medical, Argos Technologies, Inc., SP Scienceware, Teleflex Incorporated., Arthrex, Inc., Thomas Scientific, BRAND GMBH

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=22721&source=atm

See original here:
Cell Harvester Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2025 - Market Forecast

Tracing the origin of adult intestinal stem cells | Nature

Clevers, H. The intestinal crypt, a prototype stem cell compartment. Cell 154, 274284 (2013).

Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 10031007 (2007).

Shyer, A. E., Huycke, T. R., Lee, C., Mahadevan, L. & Tabin, C. J. Bending gradients: how the intestinal stem cell gets its home. Cell 161, 569580 (2015).

Nigmatullina, L. et al. Id2 controls specification of Lgr5+ intestinal stem cell progenitors during gut development. EMBO J. 36, 869885 (2017).

Tetteh, P. W. et al. Replacement of lost Lgr5-positive stem cells through plasticity of their enterocyte-lineage daughters. Cell Stem Cell 18, 203213 (2016).

van Es, J. H. et al. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. Nat. Cell Biol. 14, 10991104 (2012).

Buczacki, S. J. et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature 495, 6569 (2013).

Yui, S. et al. YAP/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell 22, 3549 (2018).

Nusse, Y. M. et al. Parasitic helminths induce fetal-like reversion in the intestinal stem cell niche. Nature 559, 109113 (2018).

Guiu, J. & Jensen, K. B. From definitive endoderm to gut-a process of growth and maturation. Stem Cells Dev. 24, 19721983 (2015).

Sumigray, K. D., Terwilliger, M. & Lechler, T. Morphogenesis and compartmentalization of the intestinal crypt. Dev. Cell 45, 183197 (2018).

Mustata, R. C. et al. Identification of Lgr5-independent spheroid-generating progenitors of the mouse fetal intestinal epithelium. Cell Reports 5, 421432 (2013).

Moor, A. E. et al. Spatial reconstruction of single enterocytes uncovers broad zonation along the intestinal villus axis. Cell 175, 11561167 (2018).

Merlos-Suarez, A. et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8, 511524 (2011).

Shyer, A. E. et al. Villification: how the gut gets its villi. Science 342, 212218 (2013).

Walton, K. D. et al. Hedgehog-responsive mesenchymal clusters direct patterning and emergence of intestinal villi. Proc. Natl Acad. Sci. USA 109, 1581715822 (2012).

Itzkovitz, S., Blat, I. C., Jacks, T., Clevers, H. & van Oudenaarden, A. Optimality in the development of intestinal crypts. Cell 148, 608619 (2012).

Sato, T. et al. Single Lgr5 stem cells build cryptvillus structures in vitro without a mesenchymal niche. Nature 459, 262265 (2009).

Fordham, R. P. et al. Transplantation of expanded fetal intestinal progenitors contributes to colon regeneration after injury. Cell Stem Cell 13, 734744 (2013).

Yui, S. et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5+ stem cell. Nat. Med. 18, 618623 (2012).

Ritsma, L. et al. Intestinal crypt homeostasis revealed at single-stem-cell level by in vivo live imaging. Nature 507, 362365 (2014).

Tian, H. et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478, 255259 (2011).

Chan, C. J., Heisenberg, C. P. & Hiiragi, T. Coordination of morphogenesis and cell-fate specification in development. Curr. Biol. 27, R1024R1035 (2017).

Hannan, N. R. et al. Generation of multipotent foregut stem cells from human pluripotent stem cells. Stem Cell Reports 1, 293306 (2013).

Spence, J. R. et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470, 105109 (2011).

Watson, C. L. et al. An in vivo model of human small intestine using pluripotent stem cells. Nat. Med. 20, 13101314 (2014).

Sun, X. et al. Directed differentiation of human embryonic stem cells into thymic epithelial progenitor-like cells reconstitutes the thymic microenvironment in vivo. Cell Stem Cell 13, 230236 (2013).

McCracken, K. W. et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516, 400404 (2014).

Kroon, E. et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat. Biotechnol. 26, 443452 (2008).

Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-fluorescent Cre reporter mouse. Genesis 45, 593605 (2007).

Means, A. L., Xu, Y., Zhao, A., Ray, K. C. & Gu, G. A CK19CreERT knockin mouse line allows for conditional DNA recombination in epithelial cells in multiple endodermal organs. Genesis 46, 318323 (2008).

Snippert, H. J. et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143, 134144 (2010).

el Marjou, F. et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186193 (2004).

Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133140 (2010).

Walton, K. D. & Kolterud, A. Mouse fetal whole intestine culture system for ex vivo manipulation of signaling pathways and three-dimensional live imaging of villus development. J. Vis. Exp. 91, e51817 (2014).

Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).

Fan, J. et al. Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis. Nat. Methods 13, 241244 (2016).

Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411420 (2018).

Read the original:
Tracing the origin of adult intestinal stem cells | Nature

StemEnhance Ultra: The Best Stem Cell Supplement

What is StemEnhance Ultra?

StemEnhance Ultra concentrates and combines extracts from natures most primitive superfoods, fresh watermicroalgae and marine macroalgae, proving the body with the ultimate in stem cell support.

StemEnhance Ultra assists the bodys inherent ability for long-term self-renewal by supporting the bodys natural release ofbone marrowstem cells.

StemEnhance Ultra provides the ultimate in stem cell support. It contains a proprietary blend of highly concentrated extracts, including Fucoidan and Cerules exclusive patented ingredients StemEnhance (AFA concentrate) & Mesenkine.

StemEnhance Ultra (AFA concentrate) is shown in studies to support the release of stem cells from the bone marrow.

Fucoidan (undaria pinnatifida) is a marinealgaewell known to support the immune system. Cerules fucoidan comes from undaria harvested from pristine environments like the Tasman Sea and Patagonia. Fucoidan from Undaria Pinnatifida has been documented to increase the number of circulatingstem cells.

Mesenkine is a unique extract from Spirulina, isolated through Cerules patented extraction process, that supports the release and homing of stem cells by balancing key messengers involved in stem cell function.

StemEnhance Ultra does not contain dairy, wheat, gluten, peanut, soy, corn, or allergens. There are no artificial flavors or colors. It is 100% vegetarian, non-GMO, and free from herbicides and pesticides.

The primary roles of adult stem cells in a living organism are to maintain and repair the tissue in which they are found. Stem cells released from the bone marrow can migrate to various tissues where they contribute to the process of tissue repair.

Suggested usage is 2 capsules 1 to 2 times daily.

The clinical studies were done using adults therefore we recommend StemEnhance Ultra for adult consumption, however there are no known contraindications for children.

StemEnhance Ultra is formulated for human consumption. We know of no reason that it may be harmful to pets. AFA and spirulina have been used in the pet nutrition industry for years. However, no studies have been done using the product for pet consumption. Please consult with your Veterinarian.

StemEnhance Ultra is the result of 16 years of research and constitutes the most efficacious and scientifically provenstem cell nutritionproduct on the market.

Through multiple clinical trials, StemEnhance Ultra was documented to optimize stem cell function in the body by increasing the number of bothstem cellsand and Endothelial Progenitor Cells (EPCs) in the bloodstream, supporting optimum renewal and repair of tissues and organs.

StemEnhance Ultra also contains Mesenkine, that was shown to increase the blood concentration of G-CSF that plays a key role in stem cell release.

See StemEnhance research here.

As stated on the label, the vegetarian capsule is made from hypromellose. Hypromellose is cellulose derivative or plant fiber.

StemEnhance Ultra ingredients are certified Kosher.It is not certified Halal.

There is an expiration date at the bottom of each bottle. StemEnhance Ultra has a shelf life of 3 years from date of manufacture. All bottles should be stored in a cool, dry place.

Yes! The Cerule products can be consumed together and were designed to enhance the beneficial effects of each other. We know of no concerning interaction between the Cerule products and other nutritional supplements.

Like many green foods, StemEnhance Ultra contains naturally occurring vitamin K, which could interfere with vitamin K blockers used to thin the blood, such as coumadin.

If you have any health condition and/or are using medication, then consult your attending health care provider before consuming any nutritional supplement.

For some people, due to their conditions and medications, they need to manage their intake of certain nutrients. Below are the amounts of naturally occurring nutrients found in the plant based ingredients within StemEnhance Ultra:

Vitamin K: around 20 ug per serving (2 capsules) Iron: 0.34 mg per serving (2 capsules) Iodine: around 4 ug per serving (2 capsules) Sodium: 9.66 mg per serving (2 capsules) PEA: >0.5%

Pregnancy and nursing are considered special conditions. We recommend that your attending Doctor(s) be made aware of any and all supplements consumed during this time. At this time, we do not advise StemEnhance Ultra consumption during pregnancy.

See the rest here:
StemEnhance Ultra: The Best Stem Cell Supplement

Adult Stem Cell Therapy – regenocyte.com

For more than 40 years, adult stem cells have been used to treat cancer patients. Recent advancements in adult stem cell therapy have been astounding. Cells from an ill patient are being used as part of the treatment. There is no possibility of the body rejecting the new tissue formed, making stem cell treatment safe and effective in achieving positive medical outcomes. It is important to note that adult stem cell therapy is not controversial because it involves the use of a patients own tissues and NOT derived from embryos.

Clinical results from cardiac, pulmonary, neurological, and vascular procedures have shown that the adult stem cell procedures are as safe as traditional procedures and are complimentary to current medical practice.

Visit our Facebook Page and read more about our real life patients and how adult stem cell therapy has changed their lives.

Adult stem cells are extracted from the patients bone marrow and fat (adipose). At Intercellular Sciences, the naturally occurring stem cells in the blood are cultivated into millions of Regenocyte Adult Stem Cells. The Regenocyte Stem Cells are produced in our international treatment center and are administered into the area of need for the patient. Once injected, they stimulate tissue re-growth and greater blood flow to the affected areas. The goal of the treatment is to replace damaged cells and to promote the growth of new blood vessels and tissues in order to help the target organ function at a greater capacity. There is no risk of rejection since the Adult Stem Cells received are directly from the patient. Regenocyte Adult Stem Cell Therapy is safe, highly effective and presents minimal risk.

Stem Cell Treatment: Cardiac

Stem Cell Treatment: Pulmonary

Stem Cell Treatment: Vascular

Stem Cell Treatment: Neurologic

If you think that adult stem cell therapy treatment may be out of reach for your health issues, it is not. Treatment is available today. Regenocyte Adult Stem Cell Therapy results have exceeded expectations. For more information on Intercellular Sciences treatments, results, and updates on advances in adult stem cell therapy, please register for our newsletter today.

To find out more today, click here or call us at (866) 216-5710

Read this article:
Adult Stem Cell Therapy - regenocyte.com

Summary: What is an Adult Stem Cell? | Stem Cells Portal …

Adult stem cells can proliferate without differentiating for a long period (a characteristic referred to as long-term self-renewal), and they can give rise to mature cell types that have characteristic shapes and specialized functions.

Some adult stem cells have the capability to differentiate into tissues other than the ones from which they originated; this is referred to as plasticity.

Adult stem cells are rare. Often they are difficult to identify and their origins are not known. Current methods for characterizing adult stem cells are dependent on determining cell surface markers and observations about their differentiation patterns in test tubes and culture dishes.

To date, published scientific literature indicates that adult stem cells have been derived from brain, bone marrow, peripheral blood, dental pulp, spinal cord, blood vessels, skeletal muscle, epithelia of the skin and digestive system, cornea, retina, liver, and pancreas; thus, adult stem cells have been found in tissues that develop from all three embryonic germ layers.

Hematopoietic stem cells from bone marrow are the most studied and used for clinical applications in restoring various blood and immune components to the bone marrow via transplantation. There are at least two other populations of adult stem cells that have been identified from bone marrow and blood.

Several populations of adult stem cells have been identified in the brain, particularly the hippocampus. Their function is unknown. Proliferation and differentiation of brain stem cells are influenced by various growth factors.

There are now several reports of adult stem cells in other tissues (muscle, blood, and fat) that demonstrate plasticity. Very few published research reports on plasticity of adult stem cells have, however, included clonality studies. That is, there is limited evidence that a single adult stem cell or genetically identical line of adult stem cells demonstrates plasticity.

Rarely have experiments that claim plasticity demonstrated that the adult stem cells have generated mature, fully functional cells or that the cells have restored lost function in vivo.

What are the sources of adult stem cells in the body? Are they "leftover" embryonic stem cells, or do they arise in some other way? And if the latter is truewhich seems to be the caseexactly how do adult stem cells arise, and why do they remain in an undifferentiated state, when all the cells around them have differentiated?

Is it possible to manipulate adult stem cells to increase their ability to proliferate in vitro, so that adult stem cells can be used as a sufficient source of tissue for transplants?

How many kinds of adult stem cells exist, and in which tissues do they exist? Evidence is accumulating that, although they occur in small numbers, adult stem cells are present in many differentiated tissues.

What is the best evidence that adult stem cells show plasticity and generate cell types of other tissues?

Is it possible to manipulate adult stem cells to increase their ability to proliferate in vitro so that adult stem cells can be used as a sufficient source of tissue for transplants?

Is there a universal stem cell? An emerging concept is that, in adult mammals, there may be a population of "universal" stem cells. Although largely theoretical, the concept has some experimental basis. A candidate, universal adult stem cell may be one that circulates in the blood stream, can escape from the blood, and populate various adult tissues. In more than one experimental system, researchers have noted that dividing cells in adult tissues often appear near a blood vessel, such as candidate stem cells in the hippocampus, a region of the brain [75].

Do adult stem cells exhibit plasticity as a normal event in vivo? If so, is this true of all adult stem cells? What are the signals that regulate the proliferation and differentiation of stem cells that demonstrate plasticity?

Excerpt from:
Summary: What is an Adult Stem Cell? | Stem Cells Portal ...

Adult Stem Cell Therapy Is A Resounding Healing Success, So …

Adult stem cell therapy is enjoying widespread success around the world, but if the FDA gets its way, it may soon be banned here in the U.S....

There have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions. It involves using the patients own stem cells, so no patent-able drugs are involved.

They are targeting the most influential stem cell scientist in the U.S., Dr. Kristin Comella in Florida.

Differentiating the Types of Stem Cell Therapy

They could be considered seeds for growing body tissues. They are mostly able to function for cellular repair and growth no matter what organ is in need of repair or healing from chronic inflammation.

There is a considerable controversy surrounding stem cell therapy research, a branch of regenerative medicine. Much of the controversy has to do with not differentiating between adult stem cell therapy and embryonic stem cell therapy.

Read: Scientists Discover That Fasting Triggers Stem Cell Regeneration & Fights Cancer

Embryonic stem cell therapy is the controversial one. It cultures or creates stem cells from terminated or aborted fetuses.

Currently, the FDA is harassing stem cell clinics that do not derive their stem cell solutions from aborted fetus tissue. They extract the stem cells from the patients own adipose tissue and inject them into areas where that same patient needs repair. Its an autologous process called adult stem cell therapy.

U.S. Stem Cell based out of South Florida is one of the clinics being targeted by the FDA, and the clinics Chief Scientist is Dr. Kristin Comella, PhD.

Many other nations have been using adult stem cell therapy successfully over the past 15 years, leaving the USA dead last in this field. The FDA is trying to make sure it stays that way and allows costly pharmaceutical versions to prevail.

Dr. Kristin Comella and her clinic have been under attack from the FDA.

This short 3-minute video was produced interviewing Dr. Comella and some of her patients.

Examining and Comparing the Different Types of Stem Cell Therapy

Human embryonic stem cell (hESC) therapy has received most of the medias attention and government support. But it is the most controversial because it involves extracting tissues from terminated human embryos, aka aborted fetuses.

In addition to moral and ethical issues, human embryonic stem cell (hESC) solutions create cells so rapidly where theyre injected they lead to cancerous tumors. To avoid that, researchers have to use immuno-suppressant drugs to curb the embryonic stem cells tendency toward cancer.

Using pharmaceutical drugs to curb hESC cancer side effect issues leads to other unexplored and unexpected side effects from those patented stem cell solutions.

But the profit motive for embryonic stem cell therapies was strong and a lot of government funds had been put into its research. Pharmaceutical companies were motivated because they could patent stem cells created from embryonic tissues.

Bone marrow stem cell therapy was among the first to depart from flawed hESC (human embryonic stem cell) therapies developed over the past two decades. Bone marrow stem cell therapy was the segue into the adult stem cell therapy movement.

Bone marrow extractions are painful, requiring general anesthesia. Its relatively difficult and expensive compared to adipose (fat) tissue stem cell harvesting.

Bone marrows high white blood cell count also encourages inflammation, making it counter-productive for patients already suffering from chronic inflammation or autoimmune disorders.

Most importantly, adipose (fat) tissue yields up to 500 times more mesenchymal stem cells than bone marrow sources, according to Dr. Comella. These are potent stem cells that can differentiate into a wide variety of other cell types. Furthermore, the adipose white blood cell count is lower than bone marrow matter.

Overactive, confused immune responses attack organs continually and create chronic inflammation and autoimmune diseases. The lower white blood cell count automatically lowers the risk of further inflammation among patients already suffering from chronic inflammation and autoimmune diseases.

The outpatient treatment involves creating a very small and shallow incision that wont require stitches on an area of skin covering adipose tissue (fat). From there, liposuction can withdraw a portion of the fat. This part of the procedure requires only a local anesthetic.

Then what is extracted is spun at high speed in a special centrifuge to isolate the stem cells which are then purified for IV drip delivery or injection into the same patient from whom it was extracted. Total costs range from five to ten thousand dollars or more in some cases.

Dr. Comella and her colleagues mission is to get adult stem cell therapy available for everyone. Private and government health insurance providers cover medical treatments that are much more expensive.

Why not cover one that would save money with its lower expense and fewer side effects?

Over the years, there have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions as well as heart and lung issues.

But the three known adverse side effect cases continually get all the media attention.

The Panama College of Cell Science, which helped launch Kristin Comellas research and development, had this to say about her:

"Perhaps the most influential clinician on the subject of adult stem cell therapy, Dr. Comella has been able to quietly develop patient treatment protocols and treat patients via collaborating physicians and health care providers using legal patient-specific FDA guidelines, including studies permitted by Institutional Review Boards, patient-specific stem cell clinical trials, and direct treatments using the patients own stem cells that are harvested and re-injected for therapeutic purposes.

"Through Dr. Comellas leadership, she and her team have trained and certified more than 700 physicians worldwide in adult stem cell therapy." (Source)

The interview below allows the energetic Dr. Kristin Comella to give a thorough and upbeat description of adult stem cell therapy.

Big Pharma Is Using the FDA to Eliminate Unregulated Adult Stem Cell Competition

Since the late 1990s, adult stem cells used therapeutically were not under the control of the FDA and the adult stem cell movement took off.

There were complaints from some MDs that the adult stem cell practice should be regulated by the FDA. The Panama College of Cell Science responded to those outcries with this statement:

"The motive in opposing adult stem cell therapy is money. The big institutions want to keep federal funding of embryonic stem cell research at a high level with the promise that cures are just around the corner despite the fact that embryonic stem cells will never be useful in any way for patient treatment because they immediately cause tumors when transplanted." (Source)

Adult stem cell therapy is an autologous treatment method. The stem cells are not lab-created. They are only isolated and purified after extracting them from the patient being treated. Injecting them back into that patient powers up the bodys own healing mechanism to overcome chronic ailments.

The FDA didnt and shouldnt have anything to do with regulating stem cells from ones own body. That situation has recently been arbitrarily and suddenly changed.

Around 2014, the FDA started tweaking their guidance rules for stem cell therapy with the purpose of getting new rules made into laws through Congress that could be interpreted according to FDA whims and enforced arbitrarily. Their agenda is to consider adult stem cells as FDA-regulated drugs.

During our phone conversation, Dr. Comella explained how the FDA ignored testimonies from adult stem cell practitioners during their 2015 public hearings regarding new guideline proposals. Then they arranged to create new rules behind closed door meetings that included pharmaceutical industry allies and insiders.

The result was that by 2017, the FDAs hands-off policy with adult stem cell therapy came to a sudden halt after years of highly successful stem cell practice.

By 2018, the FDA got nastier with the the most influential clinician on the subject of adult stem cell therapy as its target. The FDA started doing inspections of Dr. Comellas South Florida clinic that are designed for labs that manufacture drugs.

The standards for hospitals and clinics are not as strict as drug manufacturers. Those inspections were inappropriate for a clinic. But those inspections made it easier to create damaging reports.

When the inspectors came by, they demanded to go into rooms while treatments were taking place with semi-nude or nude patients, which Dr. Comella prohibited. The inspectors also demanded to view patient medical records. She allowed that after redacting their names on the copies she gave them.

For her actions to protect patients privacy, inspectors allegedly cited Dr. Comella for resisting and obstructing FDA inspections.

Soon after the inspections, the FDA served Dr. Comella with a lawsuit for practicing medicine with unapproved drugs. The drugs were only those stem cell solutions drawn from patients to be used on them.

The FDA has allegedly offered to drop the lawsuit if Dr. Comella signed an agreement to stop doing adult stem cell therapy and no longer promote it.

She refused. She said she has witnessed people leave their wheelchairs for good from this therapy. The trial is set for a Federal Court hearing beginning June 2019, in Miami, Florida.

If Dr. Comella loses this court case, adult stem cell therapy in the USA may be forced out of the country and only be available to those who can afford medical tourism.

Reference: HealthImpactNews.com

Here is the original post:
Adult Stem Cell Therapy Is A Resounding Healing Success, So ...

FDA Wants to Shut Down Adult Stem Cell Therapy as its Healing …

by Paul Fassa Health Impact News

Adult stem cell therapy is enjoying widespread success around the world, but if the FDA gets its way, it may soon be banned here in the U.S.

There have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions. It involves using the patients own stem cells, so no patent-able drugs are involved.

They are targetingthe most influential stem cell scientist in the U.S., Dr.Kristin Comella in Florida.

Many consider stem cell therapy the future of medicine. A stem cell can rebuild or create new cells in tissues, even in organ tissues other than those from which they had originally existed.

They could be considered seeds for growing body tissues. They are mostly able to function for cellular repair and growth no matter what organ is in need of repair or healing from chronic inflammation.

There is a considerable controversy surrounding stem cell therapy research, a branch ofregenerative medicine. Much of the controversy has to do with not differentiating between adult stem cell therapy and embryonic stem cell therapy.

Embryonic stem cell therapy is the controversial one. It cultures or creates stem cells from terminated or aborted fetuses.

Currently, the FDA is harassing stem cell clinics that do not derive their stem cell solutions from aborted fetus tissue. They extract the stem cells from the patients own adipose tissue and inject them into areas where that same patient needs repair. Its an autologous process called adult stem cell therapy.

U.S. Stem Cell based out of South Florida is one of the clinics being targeted by the FDA, and the clinics Chief Scientist isDr. Kristin Comella, PhD.

Many other nations have been using adult stem cell therapy successfully over the past 15 years, leaving the USA dead last in this field. The FDA is trying to make sure it stays that way and allows costly pharmaceutical versions to prevail.

Dr. Kristin Comellaand her clinichave been under attack from theFDA.

This short 3-minute video was produced interviewing Dr. Comella and some of her patients.

Human embryonic stem cell (hESC) therapy has received most of the medias attention and government support. But it is the most controversial because it involves extracting tissues from terminated human embryos, aka aborted fetuses.

In addition to moral and ethical issues, human embryonic stem cell (hESC) solutions create cells so rapidly where theyre injected they lead to cancerous tumors. To avoid that, researchers have to use immuno-suppressant drugs to curb the embryonic stem cells tendency toward cancer.

Using pharmaceutical drugs to curb hESC cancer side effect issues leads to other unexplored and unexpected side effects from those patented stem cell solutions.

But the profit motive for embryonic stem cell therapies was strong and a lot of government funds had been put into its research. Pharmaceutical companies were motivated because they could patent stem cells created from embryonic tissues.

Bone marrow stem cell therapy was among the first to depart from flawed hESC (human embryonic stem cell) therapies developed over the past two decades.Bone marrow stem cell therapy was the segue into the adult stem cell therapy movement.

Bone marrow extractions are painful, requiring general anesthesia. Its relatively difficult and expensive compared to adipose (fat) tissue stem cell harvesting.

Bone marrows high white blood cell count also encourages inflammation, making it counter-productive for patients already suffering from chronic inflammation or autoimmune disorders.

Most importantly, adipose (fat) tissue yields up to 500 times more mesenchymal stem cells than bone marrow sources, according to Dr. Comella. These are potent stem cells that can differentiate into a wide variety of other cell types. Furthermore, the adipose white blood cell count is lower than bone marrow matter.

Overactive, confused immune responses attack organs continually and create chronic inflammation and autoimmune diseases. The lower white blood cell count automatically lowers the risk of further inflammation among patients already suffering from chronic inflammation and autoimmune diseases.

The outpatient treatment involves creating a very small and shallow incision that wont require stitches on an area of skin covering adipose tissue (fat). From there, liposuction can withdraw a portion of the fat. This part of the procedure requires only a local anesthetic.

Then what is extracted is spun at high speed in a special centrifuge to isolate the stem cells which are then purified for IV drip delivery or injection into the same patient from whom it was extracted. Total costs range from five to ten thousand dollars or more in some cases.

Dr. Comella and her colleagues mission is to get adult stem cell therapy available for everyone. Private and government health insurance providers cover medical treatments that are much more expensive.

Why not cover one that would save money with its lower expense and fewer side effects?

Over the years, there have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions as well as heart and lung issues.

But the three known adverse side effect cases continually get all the media attention.

The Panama College of Cell Science, which helped launch Kristin Comellas research and development, had this to say about her:

Perhaps the most influential clinician on the subject of adult stem cell therapy, Dr. Comella has been able to quietly develop patient treatment protocols and treat patients via collaborating physicians and health care providers using legal patient-specific FDA guidelines, including studies permitted by Institutional Review Boards, patient-specific stem cell clinical trials, and direct treatments using the patients own stem cells that are harvested and re-injected for therapeutic purposes.

Through Dr. Comellas leadership, she and her team have trained and certifiedmore than 700 physicians worldwide in adult stem cell therapy. (Source)

The interview below allows the energetic Dr. Kristin Comella to give a thorough and upbeat description of adult stem cell therapy.

Since the late 1990s, adult stem cells used therapeutically were not under the control of the FDA and the adult stem cell movement took off.

There were complaints from some MDs that the adult stem cell practice should be regulated by the FDA. The Panama College of Cell Science responded to those outcries with this statement:

The motive in opposing adult stem cell therapy is money. The big institutions want to keep federal funding of embryonic stem cell research at a high level with the promise that cures are just around the corner despite the fact that embryonic stem cells will never be useful in any way for patient treatment because they immediately cause tumors when transplanted. (Source)

Adult stem cell therapy is an autologous treatment method. The stem cells are not lab-created. They are only isolated and purified after extracting them from the patient being treated. Injecting them back into that patient powers up the bodys own healing mechanism to overcome chronic ailments.

The FDA didnt and shouldnt have anything to do with regulating stem cells from ones own body. That situation has recently been arbitrarily and suddenly changed.

Around 2014, the FDA started tweaking their guidance rules for stem cell therapy with the purpose of getting new rules made into laws through Congress that could be interpreted according to FDA whims and enforced arbitrarily. Their agenda is to consider adult stem cells as FDA-regulated drugs.

During our phone conversation, Dr. Comella explained how the FDA ignored testimonies from adult stem cell practitioners during their 2015 public hearings regarding new guideline proposals. Then they arranged to create new rules behind closed door meetings that included pharmaceutical industry allies and insiders.

The result was that by 2017, the FDAs hands-off policy with adult stem cell therapy came to a sudden halt after years of highly successful stem cell practice.

By 2018, the FDA got nastier with the the most influential clinician on the subject of adult stem cell therapy as its target. The FDA started doing inspections of Dr. Comellas South Florida clinic that aredesigned for labs that manufacture drugs.

The standards for hospitals and clinics are not as strict as drug manufacturers. Those inspections were inappropriate for a clinic. But those inspectionsmade it easier to create damaging reports.

When the inspectors came by, they demanded to go into rooms while treatments were taking place with semi-nude or nude patients, which Dr. Comella prohibited. The inspectors also demanded to view patient medical records. She allowed that after redacting their names on the copies she gave them.

For her actions to protect patients privacy, inspectors allegedly cited Dr. Comella for resisting and obstructing FDA inspections.

Soon after the inspections, the FDA served Dr. Comella with a lawsuit for practicing medicine with unapproved drugs. The drugs were only those stem cell solutions drawn from patients to be used on them.

The FDA has allegedly offered to drop the lawsuit if Dr. Comella signed an agreement to stop doing adult stem cell therapy and no longer promote it.

She refused. She said she has witnessed people leave their wheelchairs for good from this therapy. The trial is set for a Federal Court hearing beginning June 2019, in Miami, Florida.

If Dr. Comella loses this court case, adult stem cell therapy in the USA may be forced out of the country and only be available to those who can affordmedical tourism.

Published on March 11, 2019

Read more:
FDA Wants to Shut Down Adult Stem Cell Therapy as its Healing ...